Schistosomiasis Clinical Trial
Official title:
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial
Previous research undertaken among adults in high endemic districts of Busia, Adjumani, Moyo
and Nebbi reported unwillingness to take preventive treatment. A particular study conducted
in primary schools of Jinja district showed that only 30% of school children took
praziquantel during the 2011 Mass Drug Administration (MDA). Fear of side effects of
praziquantel, lack of knowledge about schistosomiasis transmission and prevention and lack
of teacher support were some of the major factors associated with the low uptake. Similar
reasons for non-uptake have been reported elsewhere. Thus, measures are needed to increase
uptake of Mass Drug Administration (MDA) in Uganda. There is no doubt that health education
facilitates a better understanding of the obvious risks to health, including the knowledge
of preventing parasitic infections among primary school children. Better compliance to
treatment for schistosomiasis among school children can be achieved through implementing
carefully designed programs involving face to face education methods. Increasing knowledge
about schistosomiasis transmission and prevention and implementing measures to mitigate the
side effects attributable to praziquantel, such as providing a snack prior to drug
administration may improve uptake of the drug among school children.
Hypothesis- Provision of a pre-treatment snack is effective in improving uptake of
preventive treatment for intestinal schistosomiasis among primary school children.
Schistosomiasis is one of the most important parasitic infections in children particularly
in Sub-Saharan Africa and the age related patterns of water contact explain the high
prevalence and intensity of S. mansoni infection in children. If left untreated,
schistosomiasis results in retarded growth and impairment of cognitive function especially
among school children. Repeated treatment in the early stages of life has a long-lasting
effect on morbidity at a later age. Focusing on the delivery of regular chemotherapy to the
younger age groups produces maximum benefits and prevents chronic sequelae in adulthood.
In 2001, the World Health Organization (WHO) recommended treatment programs for
schistosomiasis to target school-age children who could be reached through the primary
school system, in collaboration with the education sector. This method was considered
affordable and cost-effective and the goal was to provide regular treatment to at least 75%
of school-age children at risk of morbidity by the year 2010.
The Ugandan national program for the control of schistosomiasis adopted the WHO
recommendations in 2003 and has since supported Mass Drug Administration (MDA) with
praziquantel, a single dose drug known for its efficacy and safety, in high burden
communities including primary schools. The current national Health Sector Strategic and
Investment Plan (HSSIP) underscores schistosomiasis as one of the diseases targeted for
elimination by the year 2015. In Jinja, implementation of the control program for
schistosomiasis started in August 2003 and has been scaled up to most of the endemic areas
in the district. Annual mass treatment using praziquantel and albendazole for
schistosomiasis and soil transmitted helminths (STH), respectively, targets all school-age
children and adults at risk of infection. Preventive measures focusing on raising awareness
on schistosomiasis include distribution of information, education and communication
materials and health education especially in the primary schools but also in the wider
communities. These are provided prior to MDA. In the primary schools, the teachers are
trained to distribute the drugs to the children and to fill the treatment registers. These
activities are supported through a parallel structure within the Ministry of Health with
external funding from the United States Agency for International Development (USAID)
channeled through Research Triangle Institute (RTI) International
Previous research undertaken among adults in high endemic districts of Busia, Adjumani, Moyo
and Nebbi reported unwillingness to take preventive treatment. A particular study conducted
in primary schools of Jinja district showed that only 30% of school children took
praziquantel during the 2011 MDA. Fear of side effects of praziquantel, lack of knowledge
about schistosomiasis transmission and prevention and lack of teacher support were some of
the major factors associated with the low uptake. Similar reasons for non-uptake have been
reported elsewhere.
Thus, measures are needed to increase uptake of MDA in Uganda. There is no doubt that health
education facilitates a better understanding of the obvious risks to health, including the
knowledge of preventing parasitic infections among primary school children. Better
compliance to treatment for schistosomiasis among school children can be achieved through
implementing carefully designed programs involving face to face education methods.
Increasing knowledge about schistosomiasis transmission and prevention and implementing
measures to mitigate the side effects attributable to praziquantel, such as providing a
snack prior to drug administration may improve uptake of the drug among school children.
Study objective:The objective of this study is to determine the efficacy of specific
messages for schistosomiasis control and prevention alone or in combination with provision
of a pre-treatment snack in improving uptake of preventive treatment for intestinal
schistosomiasis among primary school children.
Methods - Study design
This will be a stratified cluster randomized controlled trial. The reasons for adopting a
stratified cluster randomization in this study include the following:
1. The study involves evaluation of interventions (specific messages for schistosomiasis
transmission and control) which by nature, have to be implemented at a community or
school level.
2. Logistical convenience or to avoid the resentment or contamination that might occur if
unblinded interventions were provided for some individuals but not others in each
community
3. In this study, it is desired to capture the mass effect of applying an intervention to
a large proportion of primary school children e.g. reduction in the prevalence and
intensity of the infection.
4. The efficacy of some of the interventions has been established at individual levels but
it is desired to measure the effectiveness when the interventions are applied on a
community-wide basis.
- Study setting The study will be conducted in Walukuba Division, Jinja District,
South Eastern Uganda. Schistosoma mansoni is highly endemic in the Division with a
prevalence of 35% among school children [24]. Lake Victoria which borders the
Division to the south is the main source of S. mansoni infection. The Division has
a total population of 40,882. The main socio-economic activities in the area
include agriculture (subsistence farming), fishing, and petty trade between the
main land and the islands. There are 12 primary schools in the Division, majority
(8/12) of which are within a 5 km distance from the Lake.
- Implementation of MDA in the primary schools MDA in the primary schools in the
Division is implemented on an annual basis as a standalone intervention. School
teachers in-charge of health and sanitation are the focal persons for MDA. Prior
to MDA with praziquantel and albendazole, the grade teachers sensitize their
respective children about schistosomiasis prevention, including taking preventive
treatment, mobilize and prepare them to receive treatment. This is done on a group
(grade) basis. During MDA, a classroom in each school is organized for drug
administration and all children are invited indiscriminately, according to their
grade, to receive treatment. One grade is invited at a time. Praziquantel is
distributed according to height of the child using a standard dose pole. In
addition, each child receives a single tablet of albendazole. Both drugs are
distributed by the teachers and the children swallow the tablets using water under
observation of the teachers who also record the treatment in the registers.
- Randomization The 12 primary schools in Walukuba Division will be randomized into
two arms to; i) receive specific messages for schistosomiasis transmission and
control (hereafter referred to as the education arm) and ii) receive specific
messages for schistosomiasis transmission and control plus a pre-treatment snack
(hereafter referred to as the snack arm). The 12 schools will be stratified
according to uptake of praziquantel into 2 strata; low uptake stratum (<50%
uptake) and high uptake stratum (≥50% uptake). This is to ensure a good balance of
school characteristics in each arm. Randomization to the education and snack arm
will be performed within each stratum using a computer generated program in STATA
10.0 (TX,USA)
Sample size A total sample size of 1,277 children will be examined in 12 primary schools. At
95% power and a 95% confidence interval (CI), and assuming that the uptake of praziquantel
will increase from 49% (from a previous study) to 75% (WHO target), the sample size required
to detect this increase is 96 in the education arm and 96 in the snack arm (STATA 10.0, TX,
USA). This sample size will be adjusted by 5% non-response to 101. A design effect of 6.3
from a previous study will be applied to obtain a minimum sample size of 636 in the
education arm and 636 in the snack arm
-Sampling and data collection Children in grade (year) 4-6 in the 12 primary schools will be
randomly selected to participate in the study. This is because children in grade 4-6 are
about 10-14 years of age which is the peak age for schistosomiasis infection in Uganda. A
proportionate number of children will be selected from each school and grade using
probability proportional to size of the school and grade population. Systematic sampling,
using the grade registers as the sampling frame, where the names of the children are
arranged in alphabetical order, will be employed. The sampling interval will be obtained by
dividing the total population of the grade with the number of children to be studied in the
grade (N/n). After obtaining a random start from a table of random numbers, the interval
will be followed until the required number of children in each grade is obtained. Face to
face interviews with each selected child will be conducted by trained research assistants
using structured questionnaires with multiple choice questions. After the interview, stool
specimens will be collected from each child, processed and examined for S. mansoni
infection. Children who will fail to provide stool specimens for examination will be
replaced by randomly selecting an equal number of children in grade 4-6.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04115072 -
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05999825 -
Sm-p80 Schistosomiasis Challenge Study
|
Phase 2 | |
Completed |
NCT00463931 -
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
|
N/A | |
Completed |
NCT00215267 -
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
|
N/A | |
Completed |
NCT00276224 -
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
|
N/A | |
Completed |
NCT03845140 -
L-PZQ ODT in Schistosoma Infected Children
|
Phase 3 | |
Completed |
NCT01512277 -
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
|
Phase 1 | |
Active, not recruiting |
NCT03910972 -
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05085470 -
Repeated Controlled Human Schistosoma Mansoni Infection
|
N/A | |
Completed |
NCT02755324 -
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
|
N/A | |
Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
Completed |
NCT01553552 -
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
|
N/A | |
Recruiting |
NCT04589390 -
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
|
Phase 2 | |
Completed |
NCT02868385 -
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
|
Phase 3 | |
Recruiting |
NCT05762393 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
|
Phase 1 | |
Not yet recruiting |
NCT06182176 -
Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
|
N/A | |
Completed |
NCT05292391 -
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT03110757 -
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
|
Phase 1 | |
Completed |
NCT01154049 -
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
|
Phase 1 | |
Active, not recruiting |
NCT05354258 -
Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children
|
N/A |